Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions

Therapeutic Advances in Hematology

Volumn 4, Issue 1, 2013, Pages 37-41

  Tosi, Patrizia ^a   Tomassetti, Simona ^a   Merli, Anna ^a   Polli, Valentina ^a  

^a INFERMI HOSPITAL   (Italy)

Author keywords

monoclonal immunoglobulins; myeloma; serum free light chains

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BENCE JONES PROTEIN; BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN D; PARAPROTEIN; TROPONIN T;

ASSAY; BENCE JONES MULTIPLE MYELOMA; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; GOLD STANDARD; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NONSECRETORY MULTIPLE MYELOMA; OLIGOSECRETORY MULTIPLE MYELOMA; PATIENT MONITORING; PLASMACYTOMA; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; REVIEW; RISK ASSESSMENT; SERUM FREE LIGHT CHAIN ASSAY; VIRUS LOAD; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84993661399     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620712466863     Document Type: Article

References (28)

1. Bladè J. Kyle R. (1999) Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin N Am 13: 1259–1272.
2. Bradwell A. Carr-Smith H. Mead G. Harvey T. Drayson M. (2003) Serum test for assessment of patients with Bence Jones myeloma. Lancet 361: 489–491.
3. Bradwell A. Carr-Smith H. Mead G. Tang L. Showell P. Drayson M. et al. (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47: 673–680.
4. Charafeddine K. Jabbour M. Kadi R. Daher R. (2012) Extended use of serum free light chain as a biomarker in lymphoproliferative disorders. Am J Clin Pathol 137: 890–897.
5. Davids M. Murali M. Kuter D. (2010) Serum free light chain analysis. Am J Hematol 85: 787–790.
6. Dingli D. Kyle R. Rajkumar S. Nowakowski G. Larson D. Bida J. et al. (2006) Immunoglobulin free light chains and solitary plasmacytoma of the bone. Blood 108: 1979–1983.
7. Dispenzieri A. Kyle R. Katzmann J. Therneau T. Larson D. Benson J. et al. (2008) Immunoglobulin free light chains ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111: 785–789.
8. Dispenzieri A. Kyle R. Merlini G. San Miguel J. Ludwig H. Hajek R. et al. (2009) International myeloma working group guidelines for serum free light chain analysis in multiple myeloma and related disorders. Leukemia 23: 215–224.
9. Drayson M. Tang L. Drew R. Mead G. Carr-Smith H. Bradwell A. (2001) Serum-free light chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97: 2900–2902.
10. Durie B. Harousseau J. San Miguel J. Bladè J. Barlogie B. Anderson K. et al. (2006) International uniform response criteria for multiple myeloma. Leukemia 20: 1467–1473.
11. Hajek R. Cermakova Z. Pour L. Novontna H. Maisnar V. Tichy M. et al. (2007) Free light chain assays for early detection of resistance to bortezomib-based regimens. Haematologica 92: 93.
12. Hutchison C. Cockwell P. Reid S. Chandler K. Mead G.P. Harrison J. et al. (2007) Efficient removal of immunoglobulin free light chain by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 18: 886–895.
13. Hutchison C. Plant T. Drayson M. Cockwell P. Kountouri G. Basnayake K. et al. (2008) Serum free light chains aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 9: 11–18.
14. Katzmann J. Abraham R. Dispenzieri A. Lust J. Kyle R. (2005) Diagnostic performance of quantitative kappa and lambda free light chains assays in clinical practice. Clin Chem 51: 878–881.
15. Katzmann J. Clark R. Abraham R. Bryant S. Lymp J. Bradwell A. et al. (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48: 1437–1444.
16. Kumar S. Dispenzieri A. Katzmann J. Larson D. Colby C. Lacy M. et al. (2010) Serum immunoglobuin free-light chain measurement in primary amyloidosis: prognostic value and correlation with clinical features. Blood 116: 5126–5129.
17. Kumar S. Dispenzieri A. Lacy M. Hayman S. Buadi F. Colby C. et al. (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 20: 989–995.
18. Kumar S. Dispenzieri A. Lacy M. Hayman S. Buadi F. Zeldenrust S. et al. (2011) Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 86: 251–255.
19. Kyrstsonis M. Vassilakopoulos T. Kafasi N. Sachanas S. Tzenou T. Papadogiannis A. et al. (2007) Prognostic value of free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 137: 240–243.
20. Mead G. Carr-Smith H. Drayson M. Morgan G. Child J. Bradwell A. (2004) Serum free light chains for monitoring multiple myeloma. Br J Haematol 126: 348–354.
21. Pratt G. Mead G. Godfrey K. Hu Y. Evans N. Chappel M. et al. (2006) The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains. Leuk Lymphoma 47: 21–28.
22. Rajkumar S. Kyle R. Therneau T. Melton L. III Bradwell A. Clark R. et al. (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106: 812–817.
23. Sheldon J. (2007) Free light chains. Ann Clin Biochem 44: 503–505.
24. Shiels M. Landgren O. Costello R. Zingone A. Goedert J. Engels E. (2012) Free light chains and the risk of AIDS-defining opportunistic infections in HIV infected individuals. Clin Infect Dis. [Epub ahead of print]
25. Singhal S. Stein R. Vickrey E. Metha J. (2007) The serum-free light chain assay cannot replace 24-hour protein estimation in patients with plasma-cell dyscrasias. Blood 109: 143–144.
26. van Rhee F. Bolejack V. Hollmig K. Pineda-Roman M. Anaissie E. Epstein J. et al. (2007) High serum free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 110: 827–832.
27. Snozek C. Katzmann J. Kyle R. Dispenzieri A. Larson D. Therneau T. et al. (2008) Prognostic value of the serum free light chain ratio in patients with newly diagnosed multiple myeloma and proposed incorporation into the International Staging System. Leukemia 22: 1933–1937.
28. Wochner R. Strober W. Waldmann T. (1967) The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med 126: 207–221.